Business
DiaSorin S p A : signs strategic distribution agreement with McKesson Medical Surgical to expand access for the LIAISON NES molecular point‑of‑care platform
DiaSorin S p A : signs strategic distribution agreement with McKesson Medical Surgical to expand access for the LIAISON NES molecular point‑of‑care
About this update from Diasorin S.p.a.
DIASORIN SIGNS STRATEGIC DISTRIBUTION AGREEMENT WITH MCKESSON MEDICAL SURGICAL TO EXPAND ACCESS FOR THE LIAISON NES MOLECULAR POINT-OF-CARE PLATFORM AND THE FLU A/B, RSV & COVID-19 PANEL IN NON-ACUTE SETTINGS ACROSS THE UNITED STATES − Diasorin signs an exclusive distribution agreement with McKesson Medical Surgical, a diversified healthcare services company with a market-leading position in non-acute care; − The LIAISON NES enables rapid, lab-quality molecular diagnostics in near-patient settings, delivering results in ~15 minutes with a simple three-step workflow; − with this second distribution Agreement, Diasorin has achieved coverage of both the acute hospital and IDNs and non-acute physician office lab (POL) segments. Saluggia, Italy - March 19, 2026 - Diasorin (FTSE MIB: DIA) announced today a strategic distribution agreement with the distributor McKesson Medical Surgical to accelerate and support the commercialization of the LIAISON NES molecular point-of-care solution across physician offices, urgent care centers, and other decentralized testing locations in the United States. The agreement is specifically aimed at penetrating the non-acute segment, where McKesson Medical Surgical holds a market-leading position through its extensive reach, logistics capabilities, and long-standing relationships with community-based healthcare providers. Through this agreement, McKesson Medical Surgical will support the commercialization of the LIAISON NES platform and its first FDA-cleared assay, the Flu A/B, RSV & COVID-19 Panel, enabling broader access to high-quality molecular diagnostics outside the traditional hospital laboratory. The U.S. non-acute market represents a significant growth opportunity for molecular diagnostics, with more than 130,000 physician office laboratories and decentralized testing sites performing respiratory testing each year. McKesson Medical Surgical's leadership in this segment, combined with its nationwide distribution infrastructure and deep customer relationships, positions the company as a strategic distribution service provider to scale the LIAISON NES platform and support Diasorin's long-term expansion in decentralized care. "The distribution agreement ith McKesson Medical Surgical represents a key milestone in our strategy to expand molecular point-of-care testing beyond the hospital and into the settings here most ...